Bruce A Fernie1, Josianne Kollmann2, Richard G Brown3. 1. King's College London, Institute of Psychiatry, Department of Psychology, London, UK; CASCAID, South London & Maudsley NHS Foundation Trust, London, UK. Electronic address: Bruce.Fernie@kcl.ac.uk. 2. Philipps University Marburg, Institute of Psychology, Germany; King's College London, Institute of Psychiatry, Department of Psychology, London, UK. 3. King's College London, Institute of Psychiatry, Department of Psychology, London, UK.
Abstract
OBJECTIVE: Chronic neurological conditions (CNCs) affect over one million people in the UK alone. Individuals with CNCs endure an increased prevalence of comorbid depression and anxiety. Poor mental health exacerbates the cost of the treatment and management of CNCs. CBT is recommended for the treatment of depression. However the application of CBT to individuals with CNCs may be limited by disease characteristics (e.g. mobility issues restricting therapy attendance and reducing engagement with behavioural activation, as well as difficulties challenging the veracity of disease-related negative thoughts that may reflect accurate appraisals). The objective of this review is to assess the clinical effectiveness of cognitive and behavioural interventions for depressive symptoms in individuals with non-acquired, medically explained CNCs. DATA SOURCES: Searches of The Cochrane Controlled Trials Register, PubMed, and PsychINFO were conducted. RESULTS: All studies suggested that CBT is an effective treatment for depression comorbid to CNCs, however when CBT was compared to an active therapy control condition, between group differences were unstable. CONCLUSION: CBT has promise for the treatment for depression in such conditions; however treatment protocols and outcome measures should be adapted for this population. Future trials should control for non-specific effects of therapy and, as much as possible, introduce blinding into methodologies.
OBJECTIVE:Chronic neurological conditions (CNCs) affect over one million people in the UK alone. Individuals with CNCs endure an increased prevalence of comorbid depression and anxiety. Poor mental health exacerbates the cost of the treatment and management of CNCs. CBT is recommended for the treatment of depression. However the application of CBT to individuals with CNCs may be limited by disease characteristics (e.g. mobility issues restricting therapy attendance and reducing engagement with behavioural activation, as well as difficulties challenging the veracity of disease-related negative thoughts that may reflect accurate appraisals). The objective of this review is to assess the clinical effectiveness of cognitive and behavioural interventions for depressive symptoms in individuals with non-acquired, medically explained CNCs. DATA SOURCES: Searches of The Cochrane Controlled Trials Register, PubMed, and PsychINFO were conducted. RESULTS: All studies suggested that CBT is an effective treatment for depression comorbid to CNCs, however when CBT was compared to an active therapy control condition, between group differences were unstable. CONCLUSION:CBT has promise for the treatment for depression in such conditions; however treatment protocols and outcome measures should be adapted for this population. Future trials should control for non-specific effects of therapy and, as much as possible, introduce blinding into methodologies.
Authors: Sagar V Parikh; Lena C Quilty; Paula Ravitz; Michael Rosenbluth; Barbara Pavlova; Sophie Grigoriadis; Vytas Velyvis; Sidney H Kennedy; Raymond W Lam; Glenda M MacQueen; Roumen V Milev; Arun V Ravindran; Rudolf Uher Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: Charlotte Ytterberg; Charlotte Chruzander; Gunnel Backenroth; Marie Kierkegaard; Gerd Ahlström; Kristina Gottberg Journal: Int J Qual Stud Health Well-being Date: 2017-12
Authors: Chi-Yu Lin; Tomor Harnod; Cheng-Li Lin; Wei-Chih Shen; Chia-Hung Kao Journal: Int J Environ Res Public Health Date: 2019-11-15 Impact factor: 3.390
Authors: Roseanne D Dobkin; Sarah L Mann; Michael A Gara; Alejandro Interian; Kailyn M Rodriguez; Matthew Menza Journal: Neurology Date: 2020-04-01 Impact factor: 9.910
Authors: Sabrina B de Freitas; Alessandra A Marques; Mário C Bevilaqua; Marcele Regine de Carvalho; Pedro Ribeiro; Stephen Palmer; Antonio E Nardi; Gisele P Dias Journal: Braz J Psychiatry Date: 2016-08-04 Impact factor: 2.697